Increasing HPV Vaccination in a Network of Pediatric Clinics using a Multi-component Approach

Sally W. Vernon\textsuperscript{a}, Lara S. Savas\textsuperscript{a}, Ross Shegog\textsuperscript{a}, C. Mary Healy\textsuperscript{b}, Erica L. Frost\textsuperscript{a}, Sharon P. Coan\textsuperscript{a}, Efrat K. Gabay\textsuperscript{a}, Sharice M. Preston\textsuperscript{a}, Claire A. Crawford\textsuperscript{c}, Stanley W. Spinner, MD\textsuperscript{d}, Matthew A. Wilber, MD\textsuperscript{d}

\textsuperscript{a}UTHealth, The University of Texas Health Science Center Houston, School of Public Health, Center for Health Promotion and Prevention Research, Houston, Texas

\textsuperscript{b}Department of Pediatrics, Section of Infectious Diseases, Baylor College of Medicine, Houston, Texas

\textsuperscript{c}Palliative Care, Texas Children’s Hospital, Houston, Texas

\textsuperscript{d}Texas Children’s Pediatrics, Houston, Texas

BACKGROUND/INTRODUCTION

Despite continued public health efforts to increase human papillomavirus (HPV) vaccination among adolescents, initiation of the vaccine remains below the level needed to reach the Healthy People 2030 goal of 80% series completion by age 13.\textsuperscript{1} Persistent infection with high-risk HPV types (predominantly 16 and 18) cause more than 90% of cervical and anal cancers, 70% of oropharyngeal cancers, about 70% of vaginal and vulvar cancers, and more than 60% of penile cancers.\textsuperscript{2,3} In the U.S. from 2012-2015, 44,000 HPV-related cancers were reported (25,000 among women and 19,000 among men). The most common HPV-related cancers in the U.S. include oropharyngeal (19,000) and cervical (12,015).\textsuperscript{4-6} Infection with HPV types 6 and 11 is associated with the development of genital warts that cause significant morbidity in both men and women.\textsuperscript{7,8} In 2018, HPV vaccination rates among Texas youth fell below the U.S. rates as did rates of tetanus, diphtheria, and acellular pertussis (Tdap): 83.4% in Texas compared with 88.9% in the U.S. The effectiveness of HPV vaccine is acknowledged by its recognition as a Health Effectiveness Data & Information Set (HEDIS) quality assessment measure.

A number of strategies are effective in mediating increased vaccination including HPV immunization champions,\textsuperscript{9} provider assessment and feedback,\textsuperscript{10,11} reminders to cue provider treatment and prevention behaviors,\textsuperscript{11,12} provider skills training to improve HPV vaccination message delivery and overcome patient (parent) hesitancy,\textsuperscript{13} reminders
to initiate HPV vaccination and return to complete the vaccine series, and patient education and skills training programs. System-level strategies have been demonstrated effective because they triangulate approaches at various levels (organizational, provider, and patient).

Vollrath et al. found that multi-component interventions have a synergistic effect that increases provider vaccine support, improves parents’ attitudes about the vaccine, and increases immunization acceptance. The Community Guide recommends two multi-component interventions: health care system-based interventions and community-based interventions implemented in combination.

We present the results of a program to increase HPV vaccination. Funded by the Cancer Prevention and Research Institute of Texas (CPRIT), UTHealth School of Public Health and Baylor College of Medicine investigators, developed, implemented, and evaluated a multi-component program that used evidence-based strategies to increase HPV vaccination in a network of pediatric clinics in the greater Houston, Texas area.

**METHODS**

**Setting and Population**

The Adolescent Vaccination Program (AVP) was conducted from March 2016 through March 2019 within Texas Children’s Pediatrics (TCP), a network of 51 clinics located in the greater Houston, Texas, area. TCP clinics are located in five counties – Harris, Galveston, Fort Bend, Montgomery, and Brazoria -- and serve more than 100,000 children and adolescents ages 11-17 years, approximately 30% of the pediatric population in the area. Six of the clinics are part of TCP’s Community Cares Program that provides care to children regardless of the family’s financial situation or health insurance coverage.

At the time of the project, there were 249 physicians and 23 nurse practitioners, in addition to other clinical staff. Epic is the medical record system used in all TCP clinics. MyChart is the patient portal used to access a child’s medical records online, request appointments, receive test results, or communicate with the child’s physician. Our target populations were the clinic network, healthcare providers (i.e., physicians, nurses, other clinic staff), and male and female patients ages 11-17 years and their parents who attended one of the 51 TCP clinics in the network.

**Evaluation Question**

Does a multi-component program embedded in a health care system and delivered to healthcare providers and parents increase HPV vaccination initiation among adolescents ages 11 to 17 years over a 3-year period?

**Program**

For over a year preceding the funded project, we collaborated with the medical and professional staff at TCP to identify ways to improve initiation of HPV vaccination. The medical director made increasing HPV vaccination a goal for the network and worked with us to arrange six focus groups at clinics that represented the geographic and patient
diversity of the TCP population. The purpose of the focus groups was to understand attitudes and practices regarding HPV vaccination from provider and staff perspectives and to assess receptivity to the program. A total of 78 staff including physicians, physicians’ assistants, nurse practitioners, medical assistants, and practice managers attended one of the focus groups. Meetings were recorded and topics discussed were summarized by theme across the six clinics. We used information from the focus groups and our meetings with the medical director to select evidence-based strategies that were feasible to implement and sustainable within the TCP network. All six clinics agreed to serve as a Stakeholder Advisory Committee (SAC) throughout the project. Once funded, we met bi-weekly with the medical director and other TCP staff to discuss progress and identify ways to improve implementation of the program.

The program contained a suite of strategies to mediate increased vaccination comprising: 1) HPV immunization champions, 2) provider assessment and feedback (A&F), 3) continuing medical/nursing education (CME/CNE), 4) provider reminders, and 5) tailored patient (parent) reminders. Between August 2015 and March 2016 we pilot tested the program components in the six advisory clinics and made refinements based on stakeholder input before rolling them out to the other clinics in March 2016. The CME/CNE described HPV-associated disease burden, the rationale and scientific evidence behind HPV recommendations as well as describing proven effective strategies to increase HPV vaccination rates at individual, clinic and system levels. It also focused on how principles of medical ethics applied to HPV vaccination and employed real-life case vignettes to enhance provider communication skills and confidence around difficult HPV vaccine discussions.

In addition, the medical director introduced the project at regional meetings, and he used his monthly electronic newsletter to announce the rollout of the project components and to encourage all staff to engage in the program. Figure 1 describes the components of the AVP. We used a systematic process, Intervention Mapping, to develop each of the strategies. A detailed description of the development of the AVP is provided elsewhere. 

**Evaluation**

We used a single group pre/post design with an external comparison group. Our primary outcome was initiation of the HPV vaccine among 11-17 year olds based on the EHR and measured as a binary variable (yes/no). We defined initiation as at least one dose of the HPV vaccine. We calculated monthly, quarterly, and annual rates of HPV vaccine initiation for each physician’s patients and clinic in the network and for the entire network. We examined initiation over time in relation to the introduction of each of our evidence-based strategies. Our comparison group was data for Texas from the National Immunization Survey (NIS)-Teen for the years 2014 through 2018. The age group reported by NIS-Teen was 13-17 years so we used that age group as our comparison with TCP in order to examine secular trends.

We used interrupted time series analysis (ITSA) to measure the change in HPV vaccine initiation beginning with the introduction of assessment and feedback in March 2016. Other strategies were rolled out through September 2017. We continued to implement all strategies through the end of the project in March 2019. Beginning with January 2013, we had 38 months of data prior to introducing the first strategy in month 39, and 37 months of data
on or after that date. An overall model of the network measured the change in HPV vaccine initiation before and after the introduction of the program. We also compared each clinic’s experience with that of all other clinics in the network.

**Results**

Of the 108,734 patients who visited the clinic during the three years of our program, 49.4% were female, 24.2% identified as Hispanic, 13.7% as African American, 45.2% as non-Hispanic white, 5.2% as other, and 11.8% had missing information. Approximately 80% of families had commercial insurance, 13.7% had Medicaid/Medicare, 3.7% had CHIP or Tricare, and 2.1% had no insurance or were missing information. Most patients preferred English (93.3%), 4.7% preferred Spanish, 3.6% spoke another language, and 2.1% had missing information.

We examined patterns of initiation for the following factors measured from the EHR: patient age, sex, race/ethnicity, and type of insurance. There was no missing information for age or sex. For race/ethnicity 11.8% were missing information; for insurance, 2.4% were missing information.

We developed two online surveys, one for TCP physicians and another for clinical staff and managers, to assess system- and provider-level factors that may influence HPV vaccination practices. Physicians were surveyed in July-August 2015 and in January-February 2019. The survey measured organizational and patient barriers encountered when vaccinating adolescents. Variables on the surveys included previously tested items and scales that have been shown to be associated with HPV vaccination practices as well as factors identified during our clinic focus groups. The medical director and physicians on our SAC reviewed the survey, and we incorporated their feedback. The evaluation team at UTHealth emailed physicians and other staff a link to the online survey that took approximately 30 minutes to complete; those completing a survey received an electronic gift card from UTHealth. We administered the physician survey to all 227 TCP physicians, and 130 physicians completed it (57.3% response rate). For the clinic survey, we sent an electronic link to 50 practice managers and 423 advanced practice providers and other clinical staff, and we received completed surveys from 45 practice managers (90% response rate) and 375 advanced practice providers and clinical staff (88.7% response rate). Responses were well distributed across clinics with response rates ranging from 22% to 100%. Initial results of the physician survey are reported elsewhere.

We compared TCP rates with data for Texas and Houston from the NIS-Teen for the years 2014 through 2018 (Figure 2). Because the age group reported for NIS-Teen was 13-17 years, we used that age group for comparison with TCP. At baseline, initiation rates for TCP and Houston were approximately 60%; however, compared with Houston, TCP rates increased 28% vs 20.7% for Houston from baseline to year 3 (Figure 2).

September 2014 through August 2015 was the baseline year for the AVP program. Figure 3 shows the timeline for the introduction of our strategies in relation to HPV vaccine initiation rates for the overall clinic network for year 1 through the end of the program for ages.
Initiation rates increased annually from September 2015 through the end of March 2019 (Table 1 and Figure 3). ITSA analysis of the network data over 75 months showed an increase in HPV vaccination initiation of 0.396% per month from the introduction of the program at month 39 (Figure 4). Average individual clinic improvement was 0.37% per month ranging from −0.04% to 0.68% from the 39th month through March 2019. Data from four clinics were not included because they did not have data for all 75 months for the ITSA analysis. Initiation rates at baseline were slightly higher in the six advisory clinics compared with the non-advisory clinics (59% vs 56%).

Data for the 11-12 year age group, the target age group for initiating the vaccine, showed a greater percentage increase (54.2%) compared with the 13-17 year olds (29.6%) (Table 1 and Figure 5). Rates of initiation were higher for females than males at baseline and year 1, but were similar in years 2-4 (Table 1 and Figure 6). Although patterns were generally similar for all racial/ethnic groups, Hispanics and African-Americans had the highest initiation rates in all years while non-Hispanic whites had the lowest rates (Table 1 and Figure 7). Families without insurance had the lowest rates while those with Medicaid/Medicare had the highest rates (Table 1 and Figure 8). Those with commercial or other types of insurance had rates that were intermediate between those with Medicaid/Medicare and those with no insurance.

Discussion

HPV vaccination prevents most cervical, oropharynx, anus, penis, vulva and vagina cancers. Although vaccination rates are slowly increasing, they do not yet meet the American Cancer Society’s goal to have 80% of adolescents be up to date before their 13th birthday by 2026. The AVP was developed to enable providers to increase their rate of HPV vaccination. The program consists of the successive roll-out of five evidence-based strategies. It was evaluated in a large clinic network in the Houston, Texas, area that serves an estimated 30% of the pediatric population in a five-county area. During the three-year period that the program was in place, initiation of the HPV vaccine increased from approximately 50% to 80% in the areas served by TCP.

Consistent with other studies, the prevalence of HPV initiation was slightly higher in females than males in the early years of the project but rates coalesced by the end of the project. Hispanics and African Americans had higher initiation rates in all years of the project compared with non-Hispanic whites. Families without insurance had the lowest rates while those with Medicaid/Medicare had the highest.

An important strength of our project was that we worked closely with the clinic leadership for over a year prior to receiving funding. This lead time was crucial for understanding the system and establishing trusting relationships. For example, the medical director facilitated communication with the 51 clinics by using his monthly newsletter to introduce the stage of the project. We also were permitted to use internal office mail to distribute materials related to our strategies, e.g., assessment and feedback reports. Another strength of our project was clinic leadership support to develop a vaccine registry in conjunction with the network IT department to enable more accurate records of vaccination status. This was vital
for effectively targeted patient reminders. Further, clinic leadership facilitated the inclusion of branched chain decision algorithms within the Epic EHR enabling tailored reminders to providers on patient vaccine eligibility and responsiveness to changes that occurred to the guidelines during the project, e.g., change in the dose for adolescents 15 years or younger from three to two.

A limitation of the project was the pre/post design. Without a comparison group from the same population, we could not directly rule out alternative hypotheses, in particular, secular trends. We used rates for Houston from NIS-Teen as a proxy, and we observed a secular trend in both TCP and NIS-Teen data; however, the NIS-Teen Houston data showed a more gradual increase compared with TCP data, suggesting that our program was effective at increasing HPV vaccination beyond secular trends. In addition to secular trends, there were other activities that promoted and encouraged HPV vaccination both in and outside the clinic network including the Texas HPV Coalition, a group of organizations with the goal of increasing HPV vaccination in Texas (https://texashpvcoalition.org). Because TCP patients constitute a sizable proportion of NIS-Teen estimates, it is possible that estimates of initiation for Houston from NIS-Teen are overestimated. Finally, the demographics of TCP and Houston differ. According to 2018 interim census estimates, Houston is 25% non-Hispanic white, 51.6% commercially insured and 51.2% English language preference compared with TCP which is 44% non-Hispanic white, 80% commercially insured and over 90% English language preference.

The AVP is a promising program for sequenced roll-out of evidence-based strategies to increase HPV vaccination initiation in a clinic setting. The AVP was effective at increasing initiation of the HPV vaccine series among male and female adolescent patients. The program was designed as sequential but overlapping roll-out of individual components limiting our ability to test the effectiveness of each component (e.g., CME/CNE). It is possible that there was a synergistic relationship between components because improving knowledge and communication skills are likely a prerequisite to a provider’s ability to improve suboptimal vaccination rates, as highlighted in audit and feedback reports.16 Further, despite the time pressures on physicians, we demonstrated willingness to engage in physician-targeted interventions (CME and A&F). In a survey of physicians and clinic staff at the end of the program, over 80% agreed or strongly agreed with the statement “willing to use new programs”. We continued to monitor vaccination rates for a year beyond implementation of the program, and rates did not decline, suggesting that some of the strategies were sustained.

While demonstrated effective in this project, the potential for the AVP to be adopted and implemented in other clinical networks remains to be determined. Because the demographic composition of TCP and Houston differ, generalization of our results should be done cautiously. We are in the process of replicating the AVP in a smaller network of clinics with a different population in San Antonio, TX (PP180089). We also are developing a dissemination plan whereby clinics may access a web-based program that includes a stepped guide, tools and resources to guide implementation of the AVP, tailored to their clinic system’s needs (PP190041). Critical in such a plan is that clinics have the capacity to readily onboard the AVP evidence-based strategies on their own, beyond the infrastructure support.
of a funded evaluation trial. Finally, in another CPRIT project, we developed and tested an app for parents (RP150014). The app provides information to dispel myths about HPV and the vaccine and to schedule an appointment for their child.

References

1. U.S. Dept Health Human Services. Increase the proportion of adolescents who get recommended doses of the HPV vaccine - IID-08. Healthy People 2030. 2020. [https://health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination/increase-proportion-adolescents-who-get-recommended-doses-hpv-vaccine-iid-08]. Accessed 8/24/2020.

2. Douglass A, Masterson TA. Penile cancer epidemiology and risk factors: a contemporary review. Curr Opin Urol. 2019;29(2):145–149. [PubMed: 30562185]

3. Viens LJ, Henley SJ, Watson M, et al. Human Papillomavirus-Associated Cancers - United States, 2008-2012. MMWR Morb Mortal Wkly Rep. 2016;65(26):661–666. [PubMed: 27387669]

4. NIH National Cancer Institute. HPV and Cancer. 2019. [https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer].

5. Timbang MR, Sim MW, Bewley A, Farwell DG, Mantravadi A, Moore M. HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection. Hum Vaccin Immunother. 2019;15(7-8):1920–1928. [PubMed: 31050595]

6. Van Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB. Trends in Human Papillomavirus-Associated Cancers - United States, 1999-2015. MMWR Morb Mortal Wkly Rep. 2018;67(33):918–924. [PubMed: 30138307]

7. Yakely AE, Avni-Singer L, Oliveira CR, Nicolai LM. Human Papillomavirus Vaccination and Anogenital Warts: A Systematic Review of Impact and Effectiveness in the United States. Sex Transm Dis. 2019;46(4):213–220. [PubMed: 30461595]

8. Hariri S, Schuler MS, Naleway AL, et al. Human Papillomavirus Vaccine Effectiveness Against Incident Genital Warts Among Female Health-Plan Enrollees, United States. Am J Epidemiol. 2018;187(2):298–305. [PubMed: 28641366]

9. American Academy of Pediatrics. Office Strategies for Improving Immunization Rates, 2020; Electronic. Available at: [https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/immunizations/Practice-Management/Pages/office-strategies.aspx]. Accessed 3/24/2020.

10. The Community Preventive Services Task Force. Increasing appropriate vaccination: provider assessment and feedback. 2016. [https://www.thecommunityguide.org/sites/default/files/assets/Vaccination-Provider-Assessment-and-Feedback.pdf]. Accessed 1/20/2016.

11. The Community Preventive Services Task Force. Increasing appropriate vaccination: health care system-based interventions implemented in combination. 2015. Accessed 6/21/2018.

12. The Community Preventive Services Task Force. Increasing appropriate vaccination: provider reminders. 2016. [https://www.thecommunityguide.org/sites/default/files/assets/Vaccination-Provider-Reminders.pdf]. Accessed 1/4/2016.

13. Gilkey MB, McRee AL. Provider communication about HPV vaccination: a systematic review. Hum Vaccin Immunother. 2016;12(6):1454–1468. [PubMed: 26838681]

14. The Community Preventive Services Task Force. Increasing appropriate vaccination: client reminder and recall systems. In: 2015.

15. Widman CA, Rodriguez EM, Saad-Harfouche F, Twarozek AM, Erwin DO, Mahoney MC. Clinician and Parent Perspectives on Educational Needs for Increasing Adolescent HPV Vaccination. J Cancer Educ. 2018;33(2):332–339. [PubMed: 27640203]

16. Vollrath K, Thul S, Holcombe J. Meaningful Methods for Increasing Human Papillomavirus Vaccination Rates: An Integrative Literature Review. J Pediatr Health Care. 2018;32(2):119–132. [PubMed: 28918994]

17. Nicolai LM, Hansen CE. Practice- and community-based interventions to increase human papillomavirus vaccine coverage. A systematic review. JAMA Pediatr. 2015;169(7):686–692. [PubMed: 26010507]
18. Community Preventive Services Task Force. Increasing Appropriate Vaccination: Community-Based Interventions Implemented in Combination. The Community Guide. 2015.

19. Crawford CA, Shegog R, Savas LS, et al. Using Intervention Mapping to Develop an Efficacious Multi-Component Systems-Based Intervention to Increase Human Papillomavirus (HPV) Vaccination in a Large Urban Pediatric Clinic Network. J Appl Res Child. 2020;10(2).

20. Bartholomew LK, Parcel GS, Kok G, Gottlieb N, Fernandez ME. Planning Health Promotion Programs: An Intervention Mapping Approach. In: 3rd ed. San Francisco, CA: Jossey-Bass; 2011.

21. Linden A Conducting interrupted time-series analysis for single-and multiple-group comparisons. Stata J. 2015;15(2):480–500.

22. Linden A A comprehensive set of postestimation measures to enrich interrupted time-series analysis. Stata J. 2017;17(1):73–88.

23. Farias AJ, Savas LS, Fernandez ME, et al. Association of physicians perceived barriers with human papillomavirus vaccination initiation. Prev Med. 2017;105:219–225. [PubMed: 28834689]

24. Fedewa SA, Preiss AJ, Fisher-Borne M, Goding Sauer A, Jemal A, Saslow D. Reaching 80% human papillomavirus vaccination prevalence by 2026: How many adolescents need to be vaccinated and what are their characteristics? Cancer. 2018;124(24):4720–4730. [PubMed: 30257056]

25. Walker TY, Elam-Evans LD, Yankey D, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(33):718–723. [PubMed: 31437143]

26. Jeudin P, Liveright E, Del Carmen MG, Perkins RB. Race, ethnicity, and income factors impacting human papillomavirus vaccination rates. Clin Ther. 2014;36(1):24–37. [PubMed: 24417783]

27. Gilkey MB, Moss JL, McRee AL, Brewer NT. Do correlates of HPV vaccine initiation differ between adolescent boys and girls? Vaccine. 2012;30(41):5928–5934. [PubMed: 22841973]
Figure 1.
AVP system rollout of evidence-based strategies into network clinics

1. AVP Champion
   Clinic-based liaison who facilitates rollout of evidence-based strategies.

2. Assessment & Feedback Reports
   Physician- and clinic-level comparative data reports for pediatricians, clinical staff, and clinic managers.

3. Provider Education (CME/CNE)
   HCP training on HPV guidelines, ethics, evidence-based strategies, vaccination communication (proactive messaging, bundling HPV, overcoming patient barriers and rolling with resistance).

4. Provider Reminders
   EMR cues on patient HPV vaccine eligibility in the real-time during the clinic visit.

5. Tailored Patient Reminders
   Reminder messages to inform patients (parents) that they are due or overdue for HPV vaccination.
Figure 2.
HPV Vaccine Initiation Comparing TCP, Texas, and City of Houston, Ages 13-17*
*Data for Texas and City of Houston are from NIS-Teen survey years 2014-2018. NIS Teen data are only available for ages 13-17; therefore, TCP data are for the same ages.
Figure 3.
% HPV Vaccine Initiation for Patients Ages 11-17 by Year and Round of AVP Strategies
Figure 4.
Interrupted Time Series for Clinic Network
Figure 5.
HPV Vaccine Initiation over Time by Age Group
Figure 6.
HPV Vaccine Initiation by Sex, Ages 11-17 for TCP Patients
Figure 7.
HPV Vaccine Initiation by Ethnicity, Ages 11-17 for TCP Patients
Figure 8.
HPV Vaccine Initiation by Insurance Type, Ages 11-17 for TCP Patients
Table 1.

Patient Demographics and HPV Vaccine Initiation by Year, Ages 11-17

| Characteristics | Mean # Patients Per Year | % of Population | HPV Vaccine Initiation | Baseline | Year 1 | Year 2 | Year 3 | End of Project |
|-----------------|--------------------------|-----------------|------------------------|----------|-------|-------|-------|---------------|
|                 |                          |                 |                        | N        | %     | N     | %     | N     | %     | N     | %     |
| Ages 11-17      | 111,126                  |                 |                        | 100,472  | 56.4  | 107,505 | 64.4 | 115,225 | 72.6 | 121,301 | 76.8 | 123,861 | 77.4 |
| Ages 11-12      | 40,453                   | 36.4            |                        | 37,109   | 45.9  | 39,252  | 56.4 | 41,749  | 67.0 | 43,701  | 71.0 | 44,611  | 70.8 |
| Ages 13-17      | 70,673                   | 63.6            |                        | 63,363   | 62.5  | 68,253  | 69.0 | 73,476  | 75.8 | 77,600  | 80.0 | 79,250  | 81.0 |
| Female          | 54,975                   | 49.5            |                        | 49,713   | 58.9  | 53,136  | 65.7 | 56,877  | 73.0 | 60,175  | 76.6 | 61,419  | 77.3 |
| Male            | 56,151                   | 50.5            |                        | 50,759   | 45.9  | 54,369  | 63.1 | 58,348  | 72.2 | 61,126  | 77.0 | 62,442  | 77.4 |
| Non-Hispanic White | 49,387                  | 44.4            |                        | 46,807   | 52.0  | 48,568  | 59.7 | 50,765  | 67.8 | 51,408  | 73.2 | 51,947  | 72.7 |
| Non-Hispanic AfAm | 15,345                  | 13.8            |                        | 13,576   | 63.4  | 14,767  | 71.1 | 15,792  | 78.5 | 17,246  | 81.2 | 17,852  | 81.7 |
| Hispanic        | 27,534                   | 24.8            |                        | 23,302   | 63.7  | 25,743  | 71.5 | 29,014  | 78.7 | 32,077  | 81.8 | 33,109  | 82.3 |
| Other or Unknown Ethnicity | 18,860      | 17.0            |                        | 16,787   | 53.0  | 18,427  | 61.4 | 19,654  | 71.4 | 20,570  | 76.5 | 21,106  | 77.4 |
| Commercial Insurance | 89,220               | 80.3            |                        | 81,094   | 54.3  | 86,331  | 62.7 | 92,676  | 71.2 | 96,779  | 75.6 | 91,984  | 75.7 |
| Medicare/Medicaid | 18,793                 | 16.9            |                        | 16,289   | 68.2  | 18,253  | 74.1 | 19,425  | 80.8 | 21,206  | 83.8 | 28,464  | 83.7 |
| Other Insurance | 872                     | 0.8             |                        | 695      | 54.2  | 805     | 63.7 | 923     | 70.2 | 1,066   | 73.2 | 1,113   | 73.1 |
| None            | 2,240                    | 2.0             |                        | 2,394    | 47.8  | 2,116   | 51.3 | 2,201   | 59.2 | 2,250   | 63.1 | 2,300   | 65.7 |
| English Language | 103,442                | 93.1            |                        | 94,152   | 55.7  | 100,407 | 63.7 | 107,052 | 71.9 | 112,156 | 76.1 | 114,200 | 76.7 |
| Spanish Language | 5,529                   | 5.0             |                        | 4,294    | 73.7  | 4,968   | 78.7 | 5,941   | 85.4 | 6,912   | 86.9 | 7,271   | 87.2 |
| Other or Unknown Language | 1,583            | 1.4             |                        | 1,483    | 55.9  | 1,545   | 64.2 | 1,622   | 72.9 | 1,680   | 78.8 | 1,821   | 79.2 |

Baseline = 9/1/2014-8/31/2015
Year 1 = 9/1/2015-8/31/2016
Year 2 = 9/1/2016-8/31/2017
Year 3 = 9/1/2017-8/31/2018
End = 9/1/2018-2/28/2019